A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Summary

ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Psychosis Associated With Alzheimer's Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

55 to 90 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

MapLight Therapeutics

Last updated on ClinicalTrials.gov

September 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites